 Aparna Annam
Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiography, Interventional | 4 | 2024 | 116 | 2.000 |
Why?
| | Radiology | 3 | 2022 | 180 | 1.130 |
Why?
| | Thrombolytic Therapy | 2 | 2024 | 142 | 0.870 |
Why?
| | Thrombectomy | 1 | 2024 | 69 | 0.850 |
Why?
| | Endovascular Procedures | 2 | 2024 | 312 | 0.800 |
Why?
| | Radiologists | 2 | 2022 | 51 | 0.800 |
Why?
| | Hepatic Veins | 1 | 2021 | 33 | 0.730 |
Why?
| | Patient Advocacy | 1 | 2022 | 76 | 0.720 |
Why?
| | Vascular Malformations | 1 | 2021 | 52 | 0.700 |
Why?
| | Professional Role | 1 | 2022 | 167 | 0.690 |
Why?
| | Portal Vein | 1 | 2021 | 120 | 0.670 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 316 | 0.650 |
Why?
| | Wounds and Injuries | 2 | 2022 | 758 | 0.580 |
Why?
| | Spermatocele | 1 | 2015 | 2 | 0.470 |
Why?
| | Scrotum | 1 | 2015 | 27 | 0.460 |
Why?
| | Testis | 1 | 2015 | 151 | 0.440 |
Why?
| | International Educational Exchange | 1 | 2014 | 12 | 0.440 |
Why?
| | Testicular Neoplasms | 1 | 2015 | 110 | 0.420 |
Why?
| | Ultrasonography | 2 | 2022 | 759 | 0.390 |
Why?
| | Fibrinolytic Agents | 3 | 2024 | 270 | 0.360 |
Why?
| | Education, Medical, Graduate | 2 | 2023 | 486 | 0.350 |
Why?
| | Global Health | 1 | 2014 | 386 | 0.350 |
Why?
| | Pediatrics | 2 | 2021 | 1101 | 0.340 |
Why?
| | Radiology, Interventional | 2 | 2021 | 33 | 0.340 |
Why?
| | Infant, Newborn | 8 | 2024 | 6079 | 0.330 |
Why?
| | Child | 14 | 2024 | 21935 | 0.320 |
Why?
| | Anticoagulants | 2 | 2024 | 664 | 0.310 |
Why?
| | Age Factors | 3 | 2024 | 3295 | 0.290 |
Why?
| | Infant | 7 | 2024 | 9465 | 0.270 |
Why?
| | Child, Preschool | 8 | 2024 | 11074 | 0.270 |
Why?
| | Postthrombotic Syndrome | 1 | 2024 | 13 | 0.220 |
Why?
| | Humans | 23 | 2024 | 137585 | 0.210 |
Why?
| | Vascular System Injuries | 1 | 2024 | 71 | 0.200 |
Why?
| | Treatment Outcome | 5 | 2024 | 10811 | 0.200 |
Why?
| | Risk Factors | 4 | 2024 | 10388 | 0.200 |
Why?
| | Neonatology | 1 | 2022 | 29 | 0.190 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2023 | 106 | 0.190 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 229 | 0.190 |
Why?
| | Noonan Syndrome | 1 | 2022 | 17 | 0.190 |
Why?
| | Splenectomy | 1 | 2022 | 62 | 0.190 |
Why?
| | Venous Thrombosis | 1 | 2024 | 190 | 0.190 |
Why?
| | Adolescent | 7 | 2024 | 21513 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 226 | 0.180 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2021 | 25 | 0.180 |
Why?
| | Quality Indicators, Health Care | 2 | 2021 | 307 | 0.180 |
Why?
| | Nephrostomy, Percutaneous | 1 | 2021 | 9 | 0.180 |
Why?
| | Expert Testimony | 1 | 2021 | 39 | 0.170 |
Why?
| | Cholecystostomy | 1 | 2020 | 4 | 0.170 |
Why?
| | Urinary Catheterization | 1 | 2021 | 33 | 0.170 |
Why?
| | Urologic Diseases | 1 | 2021 | 41 | 0.170 |
Why?
| | Point-of-Care Systems | 1 | 2022 | 167 | 0.170 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2020 | 26 | 0.170 |
Why?
| | Education, Medical | 1 | 2023 | 266 | 0.170 |
Why?
| | Spleen | 1 | 2022 | 514 | 0.160 |
Why?
| | Empyema, Pleural | 1 | 2019 | 12 | 0.160 |
Why?
| | Chest Tubes | 1 | 2019 | 29 | 0.160 |
Why?
| | Sclerotherapy | 1 | 2018 | 20 | 0.150 |
Why?
| | Hemangioma | 1 | 2019 | 48 | 0.150 |
Why?
| | Lymphatic Abnormalities | 1 | 2018 | 19 | 0.150 |
Why?
| | Doxycycline | 1 | 2018 | 62 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 301 | 0.140 |
Why?
| | Bronchitis | 1 | 2017 | 44 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2018 | 233 | 0.130 |
Why?
| | Quality Improvement | 2 | 2021 | 1178 | 0.120 |
Why?
| | Lung Diseases | 1 | 2022 | 767 | 0.120 |
Why?
| | Lymphatic Diseases | 1 | 2014 | 22 | 0.110 |
Why?
| | Lymphography | 1 | 2014 | 10 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 628 | 0.110 |
Why?
| | Volunteers | 1 | 2014 | 29 | 0.110 |
Why?
| | Lymphatic Vessels | 1 | 2014 | 64 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2021 | 871 | 0.110 |
Why?
| | Internship and Residency | 1 | 2023 | 1147 | 0.100 |
Why?
| | Male | 7 | 2024 | 67762 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2019 | 855 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2129 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1587 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1483 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2021 | 2654 | 0.080 |
Why?
| | Lung | 1 | 2022 | 4060 | 0.070 |
Why?
| | Consensus | 2 | 2021 | 683 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3566 | 0.060 |
Why?
| | Feasibility Studies | 2 | 2022 | 956 | 0.060 |
Why?
| | Neonatologists | 1 | 2022 | 7 | 0.050 |
Why?
| | Blood Coagulation | 1 | 2024 | 255 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 134 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 816 | 0.050 |
Why?
| | Female | 4 | 2024 | 73304 | 0.050 |
Why?
| | False Positive Reactions | 1 | 2022 | 115 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2022 | 113 | 0.050 |
Why?
| | Dyspnea | 1 | 2023 | 254 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2022 | 15657 | 0.040 |
Why?
| | Pyridones | 1 | 2022 | 168 | 0.040 |
Why?
| | Thrombosis | 1 | 2024 | 371 | 0.040 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2019 | 43 | 0.040 |
Why?
| | Thoracotomy | 1 | 2019 | 75 | 0.040 |
Why?
| | Hemorrhage | 1 | 2024 | 722 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2022 | 257 | 0.040 |
Why?
| | Trauma Centers | 1 | 2022 | 421 | 0.040 |
Why?
| | Drainage | 1 | 2019 | 173 | 0.040 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.040 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 20 | 0.040 |
Why?
| | Thoracic Duct | 1 | 2017 | 5 | 0.040 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 141 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 314 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2022 | 1946 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1236 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 1060 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2014 | 34 | 0.030 |
Why?
| | Gadolinium DTPA | 1 | 2014 | 70 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1215 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Altitude | 1 | 2017 | 488 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2691 | 0.020 |
Why?
| | Contrast Media | 1 | 2014 | 467 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7604 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5131 | 0.020 |
Why?
| | United States | 1 | 2022 | 14841 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 13209 | 0.010 |
Why?
| | Adult | 1 | 2014 | 37929 | 0.010 |
Why?
|
|
Annam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|